HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity. Its highly selective and potent inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) may provide additional therapeutic benefits that could enhance treatment efficacy and durability for patients with relapsed or refractory acute myeloid leukemia (RR-AML), further improving clinical outcomes in this population. HPB-092 also has a favorable safety profile, with no major risks identi

Trial Details

NCT ID
NCT07137637
Phase
PHASE1
Sponsor
Hangzhou Polymed Biopharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • HPB-092 tablet
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Patients must meet all of the following inclusion criteria to be eligible for enrollment in the study:
  • The patient must have a diagnosis of morphologically documented relapsed or refractory acute myeloid leukemia (AML) according to the World Health O…
  • Relapsed Disease: Bone marrow blasts ≥ 5%; or Reappearance of blasts in the peripheral blood in at least two separate samples taken at least one we…
  • The patients should have a stable transfusion requirement prior to enrollment as specified in the protocol.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →